We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds
News

OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds

OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds
News

OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. (OctoPlus) announces that it has signed a new drug delivery technology evaluation contract for two compounds with a European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.

In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.

Under this contract, OctoPlus will evaluate the feasibility of two controlled release formulations that combine the active ingredients of the client with OctoPlus' proprietary drug delivery technology. If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Advertisement